Benzinga's Top #PreMarket Gainers

Myriad Genetics (NASDAQ: MYGN ) soared 14.79% to $31.20 in the pre-market trading after the company reported upbeat fiscal second-quarter results and lifted its revenue outlook for the year. Myriad also bought Crescendo Bioscience for $270 million. Omeros (NASDAQ: OMER ) shares gained 9.16% to $12.27 in the